Loading...
Loading...
Browse all stories on DeepNewz
VisitNHS Offers KIMMTRAK to HLA-A*02:01-Positive Adults with Previously Untreatable Uveal Melanoma
Dec 3, 2024, 07:10 AM
A significant advancement in cancer treatment has been announced in England, with hundreds of patients diagnosed with unresectable or metastatic uveal melanoma set to receive access to KIMMTRAK, a pioneering drug developed by Immunocore. The National Health Service (NHS) confirmed that this reimbursement agreement will allow HLA-A*02:01-positive adults to access the treatment, which is expected to extend their lives by several months. This breakthrough, described as a 'game changer,' was developed by a research team in Oxford and marks a major milestone for patients suffering from this rare and previously untreatable form of eye cancer.
View original story
Markets
Yes • 50%
No • 50%
Official announcements from Immunocore or clinical trial registries
Yes • 50%
No • 50%
Official announcements from European regulatory bodies or Immunocore
Yes • 50%
No • 50%
NHS official reports or peer-reviewed medical journals
6 to 9 months • 25%
More than 9 months • 25%
Less than 3 months • 25%
3 to 6 months • 25%
NHS official reports or peer-reviewed medical journals
Spain • 25%
Other • 25%
Germany • 25%
France • 25%
Official announcements from European regulatory bodies or Immunocore
Less than 200 • 25%
200 to 400 • 25%
400 to 600 • 25%
More than 600 • 25%
NHS official reports or press releases